Start-up unveils next frontier in drug discovery and therapeutic innovation
ThirdLaw Molecular launches its groundbreaking platform for targeted drug discovery with a 4.5-billion molecule DNA-encoded library of Spiroligomer™ macromolecules
ThirdLaw Molecular Inc., a targeted drug discovery biotech reimagining molecular therapeutics, announced the launch of its first DNA-encoded library of 4.5 billion Spiroligomer™ macromolecules. This library provides the Company and prospective partners access to a revolutionary category of molecules and the potential to transform how diseases are diagnosed and treated.
Advantages of Spiroligomer™-Based Molecules
Spiroligomer™-based molecules represent an entirely new therapeutic modality and are designed to overcome the limitations of traditional small molecules and biologics:
- Advantages over small molecules: Complex, modular, fused-ring, natural-product-like, pre-programmed structures; highly selective; fewer “off-target” effects; potential to address “undruggable” targets
- Advantages over biologics: Cell permeable; orally bioavailable; potential for improved pharmacokinetics; low immunogenicity risk; simple, scalable manufacture; stable with no special storage and handling
“Spiroligomer™ technology combines the best features of both biologics and small molecules,” said Christian Schafmeister, PhD, Founder and President of ThirdLaw Molecular. “The molecules have complex structures that allow them to selectively target proteins of interest. Yet they are small enough to penetrate cells, have favorable drug-like properties, and are synthetic in origin, making them easy to manufacture and store”.
Accelerating Discovery of Novel Therapeutics
The availability of this 4.5-billion-member DNA-encoded library of Spiroligomer™ macromolecules allows for rapid and efficient screening against biologic targets of interest. The modular design of the molecules enables rapid validation of hits, optimization of drug properties, and accelerated identification of potential lead candidates for development. Selective nanomolar-level binding of Spiroligomer™-based molecules with target proteins has already been demonstrated using this approach, representing a major milestone in the development of this ground-breaking therapeutic modality.
A Platform for Collaboration and Innovation
ThirdLaw Molecular officially opens the door to partnership opportunities with pharmaceutical companies. These collaborations will harness the platform’s potential and accelerate the development of novel therapeutics across a broad range of diseases, including those previously considered undruggable.
J. David Owens, Board Member of ThirdLaw Molecular, commented, “This represents an inflection point in the Company’s progress – and in therapeutic innovation itself. Spiroligomer™ macromolecules have the potential to redefine how we treat diseases, offering new hope to patients, and we look forward to advancing this disruptive technology to realize its promise.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.